Finding JAK2's Partners in Crime Useful in Blood, Other Disorders
ATLANTA – Nineteen years to the day after the activation of the JAK/STAT pathway by interferon was first described in the Dec. 9, 1993, issue of Nature, scientists at Incyte Corp. described the pathway from that description to the first approved inhibitor of the JAK/STAT pathway, Jakafi (ruxolitinib, Incyte Corp) at the American Society of Hematology (ASH) annual meeting last week.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter